Magnetic Nanoparticles and Thermally Responsive Polymer for Targeted Hyperthermia and Sustained Anti-Cancer Drug Delivery

  • Sarah Y. Wang
  • Michelle C. Liu
  • Kyung A. KangEmail author
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 765)


A novel cancer treatment method is being designed using a combination of iron oxide (Fe3O4) nanoparticles (IONPs) and Pluronic F-127 (PF127). IONPs have been used for heating tumors via an alternating electromagnetic (AEM) field. PF127 is a polymer possessing thermo-reversible and concentration-dependent gelation properties in aqueous solutions. PF127, as a gel, is an attractive drug delivery vehicle due to its zero-order drug release property. The combination of IONPs and PF127 would allow both short-term, tumor-specific, hyperthermic treatment, and long-term sustained drug delivery. As a preliminary study, the gelling and heating properties of IONPs/PF127 mixtures were investigated: 18% (w/w) PF127 was found to be ideal for our purpose because it gels at 28.0°C, i.e., it would be injectable at room temperature (20–25°C) and forms gel upon injection into the body (37°C). IONPs in PF127 showed little effect on gelation temperatures. The heating performance of IONPs in PF127 slightly, but linearly decreased with PF127. In the IONP concentration range of 0.01–0.05% (w/v) mixed with PF127 at 18% (w/w), the heating performance increased linearly with the increase in IONP concentration.


Nanoparticles Anti-cancer drug delivery 



Special thanks go to Ms. Jianting Wang and Dr. Robert Lupitskyy for their help. The authors also thank BASF Global for their kind donation of PF127.


  1. 1.
    Miyazaki S, Ohkawa Y, Takada M et al (1992) Anti-tumor effect of Pluronic F-127 containing Mitomycin C on Saroma 180 ascites tumor. Chem Pharm Bull 40:2224–2226CrossRefPubMedGoogle Scholar
  2. 2.
    Hatefi A, Amsden B (2002) Review: biodegradable injectable in situ forming drug delivery systems. Release 80:9–28CrossRefGoogle Scholar
  3. 3.
    Escobar-Chávez JJ, López-Cervantes M, Naïk A et al (2006) Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. J Pharm Sci 9:339–358Google Scholar
  4. 4.
    Rapoport N (2007) Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog Polym Sci 32:962–990CrossRefGoogle Scholar
  5. 5.
    Jeong B, Kim SW, Bae YH (2002) Thermosensitive sol-gel reversible hydrogels. Adv Drug Del Rev 54:37–51CrossRefGoogle Scholar
  6. 6.
    Cabana A, Ait-Kadi A, Juhász J (1997) Study of the gelation process of polyethylene oxide-polypropylene oxide-polyethylene oxide copolymer (Poloxamer 407) aqueous solutions. J Colloid Interface Sci 190:307–312CrossRefPubMedGoogle Scholar
  7. 7.
    Chung HJ, Go DH, Bae JW et al (2005) Synthesis and characterization of Pluronic® grafted chitosan copolymer as a novel injectable biomaterial. Curr Appl Phys 5:485–488CrossRefGoogle Scholar
  8. 8.
    Lenaerts V, Triqueneaux C, Quartern M et al (1987) Temperature-dependent rheological behavior of Pluronic F-127 aqueous solutions. Int J Pharm 39:121–127CrossRefGoogle Scholar
  9. 9.
    Anderson BC, Pandit NK, Mallapragada SK (2001) Understanding drug release from poly (ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels. J Control Release 70:157–167CrossRefGoogle Scholar
  10. 10.
    Jeong B, Bae YH, Kim SW (2000) Drug release from biodegradable injectable thermosensitive hydrogel of PEF-PLGA-PEG triblock copolymers. J Control Release 63:155–163CrossRefGoogle Scholar
  11. 11.
    Zhang L, Parsons DL, Navarre C et al (2002) Development and in-vitro evaluation of sustained release Poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release 85:73–81CrossRefGoogle Scholar
  12. 12.
    Moore T, Croy S, Mallapragada S et al (2000) Experimental investigation and mathematical modeling of Pluronic® F127 gel dissolution: drug release in stirred systems. J Control Release 67:191–202CrossRefGoogle Scholar
  13. 13.
    Kaowumpai W, Koolpiruck D, Viravaidya K (2007) Development of a 3D mathematical model for a doxorubicin controlled release system using pluronic gel for breast cancer treatment. Proceedings of the World Academy of Science, Engineering and Technology December: 287–292Google Scholar
  14. 14.
    Xu X, Lee P (1993) Programmable drug delivery from an erodible association polymer ­system. Pharm Res 10:1144–1152CrossRefGoogle Scholar
  15. 15.
    Hong YJ, Lee HY, Kim J (2009) Preparations and temperature-dependent release properties of Pluronic F-127 containing microcapsules prepared by a double emulsion technique. J Ind Eng Chem 15:758–762CrossRefGoogle Scholar
  16. 16.
    El-Kamel AH (2002) In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system fortimolol maleate. Int J Pharm 241:47–55CrossRefGoogle Scholar
  17. 17.
    Sanapala KK, Hewparakrama K, Kang KA (2009) Effect of AEM energy applicator configuration of magnetic nanoparticles mediated hyperthermia for breast cancer. Adv Exp Med Biol Oxygen Trans Tissue 32:143–147Google Scholar
  18. 18.
    Jin H, Kang KA (2007) Application of novel metal nanoparticles as optical/thermal agents in optical mammography and hyperthermia treatment for breast cancer. Adv Exp Med Biol Oxygen Trans Tissue 28:45–52CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sarah Y. Wang
    • 1
    • 2
  • Michelle C. Liu
    • 1
    • 2
  • Kyung A. Kang
    • 2
    Email author
  1. 1.DuPont Manual High SchoolLouisvilleUSA
  2. 2.Chemical Engineering DepartmentUniversity of LouisvilleLouisvilleUSA

Personalised recommendations